Apoptosis in spermatocytic and usual seminomas: A light microscopic and immunohistochemical study

Modern Pathology

Volumn 20, Issue 10, 2007, Pages 1036-1044

  Bishop, Elena F ^a   Badve, Sunil ^a   Morimiya, Akira ^a   Saxena, Rashmil ^a   Ulbright, Thomas M ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Proapoptotic factors; Seminoma; Spermatocytic seminoma

Indexed keywords

CASPASE 3; CD30 ANTIGEN; DEATH RECEPTOR; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53; SURVIVIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; GERM CELL TUMOR; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; MICROSCOPY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SARCOMA; SEMINOMA; SIGNAL TRANSDUCTION; SKIN LYMPHOMA; SPERMATOCYTE; STATISTICAL SIGNIFICANCE; UPREGULATION;

EID: 34548765546     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800933     Document Type: Article

References (49)

1. Cummings OW, Ulbright TM, Eble JN, et al. Spermatocytic seminoma: an immunohistochemical study. Hum Pathol 1994;25:54-59.
2. Rosai J, Silber I, Khodadoust K. Spermatocytic seminoma I. Clinicopathologic study of six cases and review of the literature. Cancer 1969;24:92-102.
3. Talerman A. Spermatocytic seminoma. Clinicopathologic study of 22 cases. Cancer 1980;45:2169-2176.
4. Scully RE. Spermatocytic seminoma of the testis. A report of 3 cases and review of the literature. Cancer 1961;14:788-794.
5. Chung PWM, Bayley AJS, Sweet J, et al. Spermatocytic seminoma: a review. Eur Urol 2004;45:495-498.
6. Ulbright TM. Testicular and paratesticular tumors. In: Mills SE, Carter D, Greenson JK, Oberman HA, Reuter VE, Stoler MH (eds). Sternberg's Diagnostic Surgical Pathology, 3rd edn. Lippincott Williams & Wilkins: Philadelphia, 2004, pp 2167-2232.
7. Woodward PJ, Mostofi FK, Talerman A, et al. Germ cell tumors. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA (eds). Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. IARC Press: Lyon, 2004, pp 221-249.
8. Masson P. Étude sur le seminome. Rev Can Biol 1946;5:361-387.
9. Damjanov I. Pathology of testicular tumors. In: Raghavan D, Scher HI, Leibel SA, Lange PH (eds). Principles and Practice of Genitourinary Oncology. Lippincott-Raven: Philadelphia, 1997, pp 653-662.
10. Pendlebury S, Horwich A, Dearnaley DP, et al. Spermatocytic seminoma: clinicopathological review of ten patients. Clin Oncol (R Coll Radiol) 1996;8:316-318.
11. Thomas G, Jones W, VanOosterom A, et al. Consensus statement on the investigation and management of testicular seminoma 1989. Prog Clin Biol Res 1990;357:285-294.
12. Ulbright TM. Germ cell neoplasms of the testis. Am J Surg Pathol 1993;17:1075-1091.
13. Matoska J, Ondrus D, Hornak M. Metastatic spermatocytic seminoma. A case report with light microscopic, ultrastructural and immunohistochemical findings. Cancer 1988;62:1197-1201.
14. True LD, Otis CN, Delprado W, et al. Spermatocytic seminoma of testis with sarcomatous transformation. A report of 5 cases. Am J Surg Pathol 1988;12:75-82.
15. Floyd CF, Ayala AG, Logothetis J, et al. Spermatocytic seminoma with associated sarcoma of the testis. Cancer 1988;61:409-414.
16. Eble JN. Spermatocytic seminoma. Hum Pathol 1994;25:1035-1042.
17. Burke AP, Mostofi FK. Spermatocytic seminoma: a clinicopathologic study of 79 cases. J Urol Pathol 1993;1:21-32.
18. Albores-Saavedra J, Huffman H, Alvarado-Cabrero I, et al. Anaplastic variant of spermatocytic seminoma. Hum Pathol 1996;27:650-655.
19. Hengartner MO. The biochemistry of apoptosis. Nature 2000;407:777-783.
20. Delhalle S, Duvoix A, Schnekenburger M, et al. An introduction to the molecular mechanisms of apoptosis. Ann NY Acad Sci 2003;1010:1-8.
21. Kumar V, Abbas AK, Fausto N. Cellular adaptations, cell injury, and cell death. In: Kumar V, Abbas AK, Fausto N (eds). Robbins and Cotran: Pathologic Basis of Disease, 7th edn. Elsevier Saunders: Philadelphia, 2005, pp 3-46.
22. Wallach D, Varfolomeev EE, Malinin NL, et al. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 1999;17:331.
23. Wajant H. The Fas signaling pathway: more than a paradigm. Science 2002;296:1635-1636.
24. Dempsey PW, Doyle SE, He JQ, et al. The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev 2003;14:193-209.
25. Green DR. Apoptotic pathways: paper wraps stone blunts scissors. Cell 2000;102:1-4.
26. Clarke LE, Bayerl MG, Bruggeman BS, et al. Death receptor apoptosis signaling mediated by FADD in CD30-positive lymphoproliferative disorders involving the skin. Am J Surg Pathol 2005;29:452-459.
27. Scorrano L, Korsmeyer SJ. Mechanisms of cytochrome release by proapoptotic BCL-2 family members. Biochem Biophys Res Commun 2003;304:437-444.
28. Ravagnan L, Roumier T, Kroemer G. Mitochondria, the killer organelles and their weapons. J Cell Physiol 2002;192:131.
29. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998;281:1322-1326.
30. Antonsson B, Martinou JC. The Bcl-2 protein family. Exp Cell Res 2000;256:50-57.
31. Cheng EH, Wei MC, Weiler S, et al. Bcl-2, Bcl-xL sequester BH3 domain-only molecules preventing Bax- and Bak-mediated mitochondrial apoptosis. Mol Cell 2001;8:705-711.
32. Debatin KM. Apoptosis pathways in cancer and cancer therapy. Cancer Immunol Immunother 2004;53:153-159.
33. Schulze-Osthoff K, Ferrari D, Los M, et al. Apoptosis signaling by death receptors. Eur J Biochem 1998;4:439-459.
34. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nature Rev Cancer 2002;2:647.
35. Kumar V, Abbas AK, Fausto N. Neoplasia. In: Kumar V, Abbas AK, Fausto N (eds). Robbins and Cotran: Pathologic Basis of Disease, 7th edn. Elsevier Saunders: Philadelphia, 2005, pp 269-342.
36. Kikuchi A, Nishikawa T. Apoptotic and proliferating cells in cutaneous lymphoproliferative disorders. Arch Dermatol 1997;133:829-833.
37. Mori M, Manuelli C, Pimpinelli N, et al. CD30-CD30 ligand interaction in primary cutaneous CD30(+) T-cell lymphomas: a clue to the pathophysiology of clinical regression. Blood 1999;94:3077-3083.
38. Paulli M, Berti E, Boveri E, et al. Cutaneous CD30(+) lymphoproliferative disorders: expression of bcl-2 and proteins of the tumor necrosis factor receptor superfamily. Hum Pathol 1998;29:1223-1230.
39. Kersemaekers AMF, van Weeren PC, Oosterhuis JW, et al. Involvement of the Fas/FasL pathway in the pathogenesis of germ cell tumors of the adult testis. J Pathol 2002;4:423-429.
40. Bargou RC, Daniel PT, Mapara MY, et al. Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis. Int J Cancer 1995;60:854-859.
41. Prokop A, Wieder T, Sturm I, et al. Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo. Leukemia 2000;14:1606-1613.
42. Sturm I, Kohne CH, Wolff G, et al. Analysis of the p53/Bax pathway in colorectal cancer: low Bax is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol 1999;17:1364-1374.
43. Leek RD, Kaklamanis L, Pezzella F, et al. Bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 1994;69:135-139.
44. Pezzella F, Turley H, Kuzu I, et al. Bcl-2 protein in non-small cell lung carcinoma. New Engl J Med 1993;329:690-694.
45. Nunez G, London L, Hockenbery D, et al. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hematopoietic cell lines. J Immunol 1990;144:3602-3610.
46. Ogretmen B, Safa AR. Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical characterization in multidrug resistant MCF-7/Adr human breast cancer cells. Oncogene 1997;14:499-506.
47. Fleischhacker M, Strohmeyer T, Imai Y, et al. Mutations of the p53 gene are not detectable in human testicular germ cell tumors. Mod Pathol 1994;7:435-439.
48. Tortola S, Marcuello E, Gonzalez I, et al. p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer. J Clin Oncol 1999;17:1375-1381.
49. Ahnen DJ, Feigl P, Quan G, et al. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer. A Southwest oncology group study. Cancer Res 1998;58:1149-1158.